Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJCN38
|
|||
| Drug Name |
REGN1193
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11] | Phase 1 | [1] | |
| Company |
Regeneron Pharmaceuticals; Sanofi
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucagon receptor (GCGR) | Target Info | Blocker | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Glucagon signaling pathway | ||||
| Reactome | Glucagon signaling in metabolic regulation | |||
| G alpha (q) signalling events | ||||
| G alpha (s) signalling events | ||||
| Glucagon-type ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02284425) Study of REGN1193 in Patients With Type 2 Diabetes Mellitus. U.S. National Institutes of Health. | |||
| REF 2 | A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers. Diabetes Obes Metab. 2018 Feb;20(2):283-291. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.